Who
George Eric Davis
EVP, Chief Legal Officer
Company insider
Files Form 4 as: EVP, Chief Legal Officer, BioMarin Pharmaceutical.
In numbers
- Trades disclosed
- 413
- Buys
- 4
- Sells
- 77
- Bought
- $44K
- Sold
- $58.0M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 20 Nov 2006
- Last trade
- 2 Sep 2026
- Last filed
- 3 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Sep 2026filed 3 Sep 2026 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Sold | $1.2M17,557 at $66.28 | filing |
| 2 Sep 2026filed 3 Sep 2026 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Sold | $1.2M17,557 at $66.28 | filing |
| 18 Mar 2026filed 19 Mar 2026 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code F | $71K1,273 at $56.05 | filing |
| 18 Mar 2026filed 19 Mar 2026 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code F | $71K1,273 at $56.05 | filing |
| 16 Mar 2026filed 17 Mar 2026 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code F | $420K7,177 at $58.51 | filing |
| 16 Mar 2026filed 17 Mar 2026 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code A | —14,570 at $0.00 | filing |
| 16 Mar 2026filed 17 Mar 2026 | BMRN BioMarin Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code A | —34,690 at $0.00 | filing |
| 16 Mar 2026filed 17 Mar 2026 | BMRN BioMarin Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code A | —34,690 at $0.00 | filing |
| 16 Mar 2026filed 17 Mar 2026 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code F | $420K7,177 at $58.51 | filing |
| 16 Mar 2026filed 17 Mar 2026 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code A | —14,570 at $0.00 | filing |
| 26 Feb 2026filed 26 Feb 2026 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Sold | $1.6M26,061 at $61.36 | filing |
| 26 Feb 2026filed 26 Feb 2026 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Sold | $1.6M26,061 at $61.36 | filing |
| 25 Feb 2026filed 26 Feb 2026 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code A | —6,177 at $0.00 | filing |
| 25 Feb 2026filed 26 Feb 2026 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code A | —6,675 at $0.00 | filing |
| 25 Feb 2026filed 26 Feb 2026 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code A | —2,372 at $0.00 | filing |
| 25 Feb 2026filed 26 Feb 2026 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code A | —6,177 at $0.00 | filing |
| 25 Feb 2026filed 26 Feb 2026 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code A | —6,675 at $0.00 | filing |
| 25 Feb 2026filed 26 Feb 2026 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code A | —2,372 at $0.00 | filing |
| 30 Apr 2025filed 13 Feb 2026 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code A | $20K375 at $54.14 | filing |
| 17 Mar 2025filed 18 Mar 2025 | BMRN BioMarin Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code A | —30,020 at $0.00 | filing |
News
Morgan Stanley Issues Pessimistic Forecast for BioMarin Pharmaceutical (NASDAQ:BMRN) Stock PriceBMRN · themarketsdaily.com · 21 Oct 2026BioMarin Pharmaceutical's (BMRN) Overweight Rating Reaffirmed at Cantor FitzgeraldBMRN · dailypolitical.com · 20 Oct 2026Critical Survey: XTL Biopharmaceuticals (NASDAQ:XTLB) & BioMarin Pharmaceutical (NASDAQ:BMRN)BMRN · tickerreport.com · 18 Oct 2026
0 headlines in the last 90 days name George Eric Davis; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.